- NCIt
- C115132
Loading cancer entity…
Loading cancer entity…
Clinical trials
30 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | terminated | Phase 2 | 15 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07274774 | SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma | recruiting | Phase 2 | 184 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04605731 | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | active not recruiting | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07449637 | Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma. | not yet recruiting | — | 200 | Sohag UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04736121 | Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients(DOORwaY90) | active not recruiting | N/A | 100 | Sirtex MedicalINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06631326 | HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) | completed | — | 244 | First Hospital of China Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07368530 | Using Machine Learning to Identify Responders to TACE or HAIC for uHCC | completed | — | 3,000 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | recruiting | Phase 3 | 262 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04828486 | Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer | completed | Phase 2 | 14 | Mayo ClinicOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05622071 | Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions(HESTIA) | completed | Phase 2 | 50 | UNICANCEROTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06230328 | Brazilian Reality of Hepatocellular Carcinoma(BRA-HEP) | completed | — | 300 | AstraZenecaINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT02940496 | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05810402 | Liver Cancer and Immunotherapy in the Liquid Biopsy Era(LILIPSY) | recruiting | N/A | 60 | University Hospital, MontpellierOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06632093 | HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | recruiting | — | 84 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05883176 | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria(B-TACE) | unknown | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | terminated | Early Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04992143 | TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | unknown | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT05214339 | A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT01900002 | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT04780789 | Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization | completed | — | 61 | Brno University HospitalOTHER | 0 | Mar 4, 2021 | clinicaltrials |
| NCT01666756 | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT03652896 | Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma | unknown | N/A | 60 | Huazhong University of Science and TechnologyOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT03515252 | Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer | completed | Phase 1 | 20 | Ivy Life Sciences, Co., LtdINDUSTRY | 0 | May 9, 2018 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02578602 | MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer | completed | Phase 1 | 26 | University of Southern CaliforniaOTHER | 1 | Oct 19, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 4, 2026source: clinicaltrials